Loading
companiesCompany
Summit Therapeutics
Summit Therapeutics holds Western rights to ivonescimab and is running the global HARMONi trials.
Overview
Summit Therapeutics, based in Miami and listed as SMMT, holds the Western rights to ivonescimab, Akeso's PD-1 by VEGF bispecific antibody, and is running the global HARMONi trials. HARMONi-3 tests it in first-line non-small-cell lung cancer and HARMONi-7 in PD-L1-high disease, both phase 3, and the company's biologics licence strategy follows the overall survival result of the HARMONi trial. OnCo links it to non-small-cell lung cancer and cutaneous squamous cell carcinoma, to HARMONi-A, and to the HARMONi-2 paper in which ivonescimab beat pembrolizumab head to head. Whether a Chinese head-to-head win can be reproduced in a Western population, and whether the FDA will accept it, is the open question the company exists to answer. Ivonescimab has its own page.
Headquarters
Miami, FL, US
Scorecard
All companies#157of 1244 companies, score 39
- approved products +6
- targets +4
- modalities +2
- regions +1
- 24-month regulatory events +4
- registry trials +22
1 approved, 0 in phase 3, 0 earlier, 2 targets, 116 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2022-12-06 | Akeso to Summit Therapeutics Ivonescimab (AK112, SMT112), PD-1 x VEGF bispecific | Licence | $500m | up to $5.0bn | source |
Catalysts
What is due next- 2027expectedHARMONi-3: ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy, first-line NSCLC
The first head-to-head test of the PD-1 x VEGF bispecific against pembrolizumab in a Western population. Timing is our estimate from the registry record; the sponsor has not given a date. Source
Type
Biotech · SMMT
Stage
Public
Website
ApprovedBispecific antibody (PD-1×VEGF)
A Chinese bispecific that beat Keytruda head-to-head on progression-free survival in lung cancer, the first drug ever to do so.
Similar pages
- TrialHARMONi-2
Shares HARMONi-A, HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer, Ivonescimab, PD-L1-high non-small-cell lung cancer without a driver mutation.
- PersonWenfeng Fang
Shares HARMONi-A, Ivonescimab, Non-small-cell lung cancer.
- PersonQing Zhou
Shares HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer, Ivonescimab, Non-small-cell lung cancer.
- PersonMichelle Xia (Xia Yu)
Shares HARMONi-A, Ivonescimab.
- PersonCaicun Zhou
Shares HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer, Ivonescimab, Non-small-cell lung cancer.
- PersonLi Zhang
Shares HARMONi-A, Non-small-cell lung cancer.
- TechnologyBispecific antibodies
Shares A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer, Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1, A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma, HARMONi-3.
- IdeaConfirm ultra-low-dose immunotherapy so it can be afforded where most patients live
Shares HARMONi-3, Non-small-cell lung cancer.
cancers
fronts
drugs
ApprovedBispecific antibody (PD-1×VEGF)
trials
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerA Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaA Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung CancerClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1HARMONi-3HARMONi-AIvonescimab Alone And With Carboplatin/Pemetrexed For NSCLCPhase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal CancerPhase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung CancerPhase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain MetsPhase III Study of AK112 for NSCLC PatientsPhase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerTesting Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases